Reich, K., Simpson, E. L., Langley, R., Warren, R. B., Costanzo, A., Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., de Bruin-Weller, M., & Blauvelt, A. (2022). Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, 6(6), s79. https://doi.org/10.25251/skin.6.supp.79